Clinical Trial Update: Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy

View source ↗

Summary

This clinical trial update reports the results of a long-term non-interventional study in Italy evaluating the impact of Mayzent on patients with Active Seconda…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Active Secondary Progressive Multiple Sclerosis

Drugs mentioned

• MAYZENT (siponimod)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Active Secondary Progressive Multiple Sclerosis | Status: COMPLETED